Cart
sales@molnova.com
Home - Products - JAK/STAT Signaling - STAT - Suptavumab

Suptavumab

CAS No. 1629615-23-1

Suptavumab( —— )

Catalog No. M36790 CAS No. 1629615-23-1

Suptavumab (REGN2222) is a human monoclonal antibody that neutralizes conserved epitopes on subtypes A and B of RSV, making it useful for studying RSV infections and the respiratory system.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 499 Get Quote
5MG 820 Get Quote
10MG 1311 Get Quote
25MG 1822 Get Quote
50MG 2548 Get Quote
100MG 3357 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Suptavumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Suptavumab (REGN2222) is a human monoclonal antibody that neutralizes conserved epitopes on subtypes A and B of RSV, making it useful for studying RSV infections and the respiratory system.
  • Description
    Suptavumab (REGN2222) is a human monoclonal antibody. Suptavumab can bind and block a conserved epitope on RSV A and B subtypes. Suptavumab can be used for the research of RSV infection.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    JAK/STAT Signaling
  • Target
    STAT
  • Recptor
    RSV
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1629615-23-1
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Sim?es EAF, et al. Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants. Clin Infect Dis. 2021 Dec 6;73(11):e4400-e4408. ?
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • QD 232

    QD 232 is a novel quinazolinedione-based redox modulator that potently inhibits Src/FAK and STAT3 phosphorylation.

  • S3I-201

    S3I-201 shows potent inhibition of STAT3 DNA-binding activity with IC50 of 86 μM in cell-free assays, and low activity towards STAT1 and STAT5.

  • MMPP

    MMPP is a novel VEGFR2 inhibitor with anti-inflammatory and potential anticancer activity, inhibits STAT3, inhibits angiogenesis via VEGFR2/AKT/ERK/NF-kappaB pathway, and can be used to alleviate myocardial injury.

Sign In Join Free